Ritonavir
- Generic Name
- Ritonavir
- Brand Names
- Kaletra, Norvir, Paxlovid, Viekira Pak, Ritonavir Mylan
- Drug Type
- Small Molecule
- Chemical Formula
- C37H48N6O5S2
- CAS Number
- 155213-67-5
- Unique Ingredient Identifier
- O3J8G9O825
- Background
Ritonavir is an HIV protease inhibitor that interferes with the reproductive cycle of HIV. Although it was initially developed as an independent antiviral agent, it has been shown to possess advantageous properties in combination regimens with low-dose ritonavir and other protease inhibitors. It is now more commonly used as a booster of other protease inhibi...
- Indication
Ritonavir is indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection.
...
- Associated Conditions
- Chronic hepatitis C genotype 1a, Chronic hepatitis C genotype 1b, Human Immunodeficiency Virus Type 1 (HIV-1) Infection, Mild, moderate Novel Coronavirus Infectious Disease (COVID-19)
- Associated Therapies
- -
A Study to Learn About the Study Medicine (Nirmatrelvir Plus Ritonavir) in Pregnant Women With COVID-19
- First Posted Date
- 2022-05-23
- Last Posted Date
- 2024-10-14
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 49
- Registration Number
- NCT05386472
- Locations
- ๐บ๐ธ
University of Alabama at Birmingham Women & Infant Center, Birmingham, Alabama, United States
๐บ๐ธUniversity of Alabama at Birmingham/Center for Women's Reproductive Health, Birmingham, Alabama, United States
๐บ๐ธAbby's Research institute, Phoenix, Arizona, United States
EPIC-Peds: A Study to Learn About the Study Medicine Called PF-07321332 (Nirmatrelvir)/Ritonavir in Patients Under 18 Years of Age With COVID-19 That Are Not Hospitalized But Are at Risk for Severe Disease
- First Posted Date
- 2022-03-02
- Last Posted Date
- 2024-11-18
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 160
- Registration Number
- NCT05261139
- Locations
- ๐บ๐ธ
University of Alabama at Birmingham - School of Medicine, Birmingham, Alabama, United States
๐บ๐ธPhoenix Children's Hospital, Phoenix, Arizona, United States
๐บ๐ธArkansas Children's Hospital, Little Rock, Arkansas, United States
Once Daily Dosing of Lonafarnib Co-administered With Ritonavir for Treatment of Chronic Hepatitis D Virus Infection
- Conditions
- Interventions
- First Posted Date
- 2022-02-08
- Last Posted Date
- 2023-05-06
- Lead Sponsor
- Soroka University Medical Center
- Target Recruit Count
- 30
- Registration Number
- NCT05229991
- Locations
- ๐ณ๐ฟ
New Zealand Liver Transplant Unit, Auckland City Hospital, Auckland, New Zealand
๐น๐ทDepartment of Gastroenterology and Hepatology, Koรง University Medical School, Istanbul, Turkey, Istanbul, Turkey
๐ฎ๐ฑSoroka UMC, Be'er Sheva, Israel
A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2021-12-09
- Last Posted Date
- 2024-10-03
- Lead Sponsor
- DualityBio Inc.
- Target Recruit Count
- 766
- Registration Number
- NCT05150691
- Locations
- ๐บ๐ธ
Kapi'olani Medical Center for Women and Children, Honolulu, Hawaii, United States
๐บ๐ธWomen's Cancer Care, Covington, Louisiana, United States
๐บ๐ธHoly Cross Hospital, Silver Spring, Maryland, United States
Food Effect Study to Evaluate the Effect of High-Fat Meal on the Relative Bioavailability of PF-07321332 Boosted With Ritonavir in Healthy Adult Participants
- Conditions
- Interventions
- First Posted Date
- 2021-11-22
- Last Posted Date
- 2023-10-05
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 12
- Registration Number
- NCT05129475
- Locations
- ๐บ๐ธ
New Haven Clinical Research Unit, New Haven, Connecticut, United States
A Study of a Potential Oral Treatment to Prevent COVID-19 in Adults Who Are Exposed to Household Member(s) With a Confirmed Symptomatic COVID-19 Infection
- Conditions
- Interventions
- First Posted Date
- 2021-09-17
- Last Posted Date
- 2023-05-06
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 2954
- Registration Number
- NCT05047601
- Locations
- ๐บ๐ธ
Accellacare, Ames, Iowa, United States
๐จ๐ดClinica de la Costa LTDA., Barranquilla, Atlantico, Colombia
๐ญ๐บMedifarma-98 Kft., Nyiregyhaza, Hungary
Evaluation of Protease Inhibition for COVID-19 in Standard-Risk Patients (EPIC-SR).
- First Posted Date
- 2021-08-18
- Last Posted Date
- 2023-08-14
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 1440
- Registration Number
- NCT05011513
- Locations
- ๐บ๐ธ
Eastern Research Inc, Hialeah, Florida, United States
๐บ๐ธPremium Medical Research Corp, Miami, Florida, United States
๐บ๐ธSouth Florida Research Center, Inc., Miami, Florida, United States
Study of PBI-0451 in Healthy Subjects.
- First Posted Date
- 2021-08-18
- Last Posted Date
- 2022-06-03
- Lead Sponsor
- Pardes Biosciences, Inc.
- Target Recruit Count
- 130
- Registration Number
- NCT05011812
- Locations
- ๐ณ๐ฟ
Auckland City Hospital, Auckland, New Zealand
Study to Estimate the Effects of Hepatic Impairment on the Pharmacokinetics (PK) of PF-07321332
- First Posted Date
- 2021-08-13
- Last Posted Date
- 2023-09-06
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 17
- Registration Number
- NCT05005312
- Locations
- ๐บ๐ธ
Prism Research LLC dba Nucleus Network, Saint Paul, Minnesota, United States
๐บ๐ธOrange County Research Center, Tustin, California, United States
EPIC-HR: Study of Oral PF-07321332/Ritonavir Compared With Placebo in Nonhospitalized High Risk Adults With COVID-19
- First Posted Date
- 2021-07-13
- Last Posted Date
- 2023-02-09
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 2246
- Registration Number
- NCT04960202
- Locations
- ๐บ๐ธ
Cahaba Research Inc, Pelham, Alabama, United States
๐บ๐ธThe Institute for Liver Health dba Arizona Clinical Trials, Tucson, Arizona, United States
๐บ๐ธHope Clinical Research, Canoga Park, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.